Holen Sie sich die Stockscreener-App
56.02
6.51%
-3.90
Schlusskurs vom Vortag:
$59.92
Offen:
$57.11
24-Stunden-Volumen:
706.16K
Relative Volume:
0.72
Marktkapitalisierung:
$1.07B
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-38.37
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
-8.04%
1M Leistung:
-7.48%
6M Leistung:
+7,349%
1J Leistung:
+4,112%
1-Tages-Spanne:
$55.69
$58.51
1-Wochen-Bereich:
$55.69
$66.92
52-Wochen-Spanne:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Vergleichen Sie NKTR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
56.02 | 1.14B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 9.5%Time to Sell? - MarketBeat
Is it time to cut losses on Nektar TherapeuticsQuarterly Investment Review & Reliable Breakout Forecasts - newser.com
Why Nektar Therapeutics stock remains on buy lists2025 AllTime Highs & Verified Chart Pattern Trade Signals - newser.com
Can Nektar Therapeutics hit a new high this monthJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Why retail investors pile into Nektar Therapeutics stockBond Market & Weekly High Potential Stock Alerts - newser.com
Is Nektar Therapeutics trending in predictive chart modelsJuly 2025 Closing Moves & Long-Term Capital Growth Strategies - newser.com
Is Nektar Therapeutics stock a good choice for value investorsMarket Sentiment Report & Weekly Setup with High ROI Potential - newser.com
Pattern recognition hints at Nektar Therapeutics upsideGlobal Markets & Proven Capital Preservation Tips - newser.com
Published on: 2025-11-03 04:48:43 - newser.com
Why Nektar Therapeutics stock remains undervaluedJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
Will Nektar Therapeutics stock benefit from AI adoptionPortfolio Gains Summary & Community Consensus Picks - newser.com
Can Nektar Therapeutics (ITH0) stock sustain free cash flow2025 Price Momentum & AI Forecasted Entry and Exit Points - newser.com
What margin trends mean for Nektar Therapeutics stockJuly 2025 Trade Ideas & Capital Efficient Trading Techniques - newser.com
Using economic indicators to assess Nektar Therapeutics potential2025 Year in Review & Daily Momentum Trading Reports - newser.com
Moody Aldrich Partners LLC Invests $1.17 Million in Nektar Therapeutics $NKTR - MarketBeat
Will Nektar Therapeutics continue its uptrend2025 Analyst Calls & AI Driven Price Predictions - newser.com
Nektar Therapeutics (NKTR): Valuation Reset as REZOLVE-AD Phase 2b Data and Analyst Optimism Drive Investor Interest - simplywall.st
Is Nektar Therapeutics (ITH0) stock undervalued at current priceQuarterly Profit Report & Weekly Watchlist for Consistent Profits - newser.com
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 1-Year HighShould You Buy? - MarketBeat
Is Nektar Therapeutics (ITH0) stock a top dividend aristocrat candidateJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
Nektar Therapeutics stock hits 52-week high at 65.97 USD By Investing.com - Investing.com Australia
Nektar Therapeutics (NKTR) Is Up 8.0% After Late-Breaking Phase 2b Rezpegaldesleukin Data Announcement - Sahm
Nektar Therapeutics stock hits 52-week high at 65.97 USD - Investing.com
Best data tools to analyze Nektar Therapeutics stockQuarterly Earnings Report & Verified Trade Idea Suggestions - newser.com
Nektar Therapeutics (NKTR): Taking a Fresh Look at Valuation After Recent Share Price Rebound - Yahoo Finance
Can volume confirm reversal in Nektar TherapeuticsJuly 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - PR Newswire
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Nektar Therapeutics $NKTR Holdings Trimmed by Deuterium Capital Management LLC - MarketBeat
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):